Our Technology - MAVERICS Artificial Graft

The Medical 21 graft is a small, flexible tube encased in a nitinol scaffold that replaces the need for blood vessel harvesting in the heart bypass surgery patient, creating a more efficient, cost-effective, and less invasive procedure.

Our Technology - MAVERICS Artificial Graft

By eliminating traditional vein harvesting, the MAVERICS technology can reduce a patient’s pain, discomfort, wound healing complications, disfigurement, and length of post-op stay. Medical 21’s graft system can benefit surgeons by reducing operating room time and reducing costs through shorter hospital stays, fewer post-op complications, and lower vein harvesting costs per patient.

The MAVERICS graft will be available to all patients regardless of the condition of their arteries and veins, giving all bypass procedure candidates an opportunity for coronary artery bypass graft surgery.

Medical 21 Technology Image 1

Product Overview

Learn more about our stronger, more flexible, and biocompatible graft.

Needs

Med21 Technology Global Needs

Cardiovascular disease (CVD) is the #1 cause of death globally.

Med21 Technology Global Needs

Roughly two billion adults have a risk for heart disease.

  • Worldwide obesity has tripled since 1975.
Med21 Technology Global Needs

Minimally invasive treatments for cardiac blockages, such as stents, can be helpful in some cases, but bypass surgery is the preferred option when more than two arteries are involved.

  • Bypass surgery is typically the method that provides more complete revascularization.
Med21 Benefits

Between 800,000 and 1 million heart bypass surgeries are performed each year worldwide, requiring 2.5 million to 3.5 million grafts.

Med21 Benefits

Each bypass surgery requires the surgical team to create additional incisions to harvest vessels from a patient’s arms or legs to use in the bypass procedure, which can lead to post-op complications, pain, and a host of issues for a patient and their care team.

Benefits

Med21 Benefits

The Medical 21 graft eliminates the need for vessel harvesting, which we anticipate could also:

  • Decrease the risk of infection
  • Prevent additional scarring, pain, and other post-op complications
  • Open the door to people with severe diabetes, varicose veins, and amputations
  • Make it likely that patients spend at least one less day in the ICU following surgery
  • Significantly decrease procedure time for the surgical team

Contact Us

Title/Role (*Optional)

The form was sent successfully.

This Opportunity is Open to Everyone

Medical 21 is open to investors through Regulation A+ fundraising, which allows accredited investors and the general public alike to participate.

Learn how you can join us in reshaping the future of cardiac bypass surgery.